First Patients Dosed in Phase 3 Trials Testing Tavapadon in Parkinson’s Patients

[JayPwP]

parkinsonsnewstoday.com/202...

[park_bear]

Said to be a better dopamine agonist:

cerevel.com/compounds/tavap...

" Tavapadon was designed to improve motor symptoms in Parkinson’s disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations. Tavapadon is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, which can lead to dyskinesias and exacerbation of “off” time."

Versus, for example,

en.wikipedia.org/wiki/Dopam...

" Pramipexol

Pramipexol is a highly active non-ergot D2-like receptor agonist with a higher binding affinity to D3 receptors rather than D2 or D4 receptors. The mechanism of action of pramipexole is mostly unknown, it is thought to be involved in the activation of dopamine receptors in the area of the brain where the striatum and the substantia nigra is located. This stimulation of dopamine receptors in the striatum may lead to the better movement performance.[24] "

We shall see. Dopamine agonist medications could certainly use improvement.